Tvardi Therapeutics (NASDAQ:TVRD) Shares Up 2.6% – Still a Buy?

Tvardi Therapeutics, Inc. (NASDAQ:TVRD)’s share price was up 2.6% on Wednesday . The company traded as high as $2.03 and last traded at $1.95. Approximately 167,959 shares changed hands during mid-day trading, a decline of 56% from the average session volume of 385,365 shares. The stock had previously closed at $1.90.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on TVRD. HC Wainwright began coverage on shares of Tvardi Therapeutics in a report on Monday, June 8th. They set a “buy” rating and a $9.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, April 10th. BTIG Research reiterated a “buy” rating and issued a $15.00 target price on shares of Tvardi Therapeutics in a research report on Wednesday, April 1st. Finally, Wall Street Zen lowered shares of Tvardi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 4th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Tvardi Therapeutics has an average rating of “Moderate Buy” and an average target price of $39.80.

Tvardi Therapeutics Price Performance

The stock has a 50-day moving average of $3.09 and a 200-day moving average of $3.56. The company has a market cap of $18.95 million, a PE ratio of -0.65 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Friday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.08). Research analysts expect that Tvardi Therapeutics, Inc. will post -2.39 EPS for the current year.

Hedge Funds Weigh In On Tvardi Therapeutics

A number of large investors have recently modified their holdings of the company. American Financial Group Inc. bought a new position in Tvardi Therapeutics during the fourth quarter valued at approximately $962,000. Vestal Point Capital LP purchased a new stake in shares of Tvardi Therapeutics in the 3rd quarter valued at $6,508,000. Geode Capital Management LLC purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at $2,617,000. Invesco Ltd. bought a new position in shares of Tvardi Therapeutics during the 3rd quarter valued at $3,219,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Tvardi Therapeutics by 246.3% during the 4th quarter. Renaissance Technologies LLC now owns 104,500 shares of the company’s stock valued at $449,000 after purchasing an additional 74,325 shares during the last quarter. 44.66% of the stock is owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.